• 1.廣東深圳寶安區(qū)人民醫(yī)院普外科(深圳 518101);;
  • 2.湖州師范學(xué)院醫(yī)學(xué)院創(chuàng)新實(shí)驗(yàn)室（浙江湖州 313000）;

目的 探討丙型肝炎病毒（HCV）的F蛋白對(duì)肝星形細(xì)胞生長(zhǎng)及膠原蛋白表達(dá)的影響。方法 將含有HCV f基因的pcDNA3.1-f質(zhì)?；騪cDNA3.1空載體分別轉(zhuǎn)染肝星形細(xì)胞株LX2，G418篩選后獲得穩(wěn)定轉(zhuǎn)染的細(xì)胞，分別命名為L(zhǎng)X-f細(xì)胞或LX-p細(xì)胞，MTT法測(cè)定細(xì)胞增殖情況，ELISA法檢測(cè)細(xì)胞分泌的Ⅰ型和Ⅲ型膠原蛋白含量。結(jié)果 自培養(yǎng)24 h起，LX-f細(xì)胞各時(shí)間點(diǎn)的增殖率均大于LX-p細(xì)胞（P lt;0.01）。培養(yǎng)48 h時(shí)，LX-f細(xì)胞的Ⅰ型膠原蛋白及Ⅲ型膠原蛋白分泌量分別為（25.89±0.42） ng/ml和（18.21±0.49） ng/ml，明顯高于LX-p細(xì)胞的（22.65±0.49） ng/ml和（15.29±0.62） ng/ml（P lt;0.01）。結(jié)論 HCV的F蛋白能促進(jìn)肝星形細(xì)胞增殖，并上調(diào)細(xì)胞分泌Ⅰ型和Ⅲ型膠原蛋白，誘發(fā)肝纖維化。

引用本文： 王甘露,邵圣文,徐伯贏,盧添寶,段勁,顧福萍. 丙型肝炎病毒F蛋白上調(diào)肝星形細(xì)胞膠原表達(dá)△. 中國(guó)普外基礎(chǔ)與臨床雜志, 2010, 17(12): 1258-1260. doi: 復(fù)制

1. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome [J]. Science, 1989; 244(4902): 359-362.
2. Sklan EH, Charuworn P, Pang PS, et al. Mechanisms of HCV survival in the host [J]. Nat Rev Gastroenterol Hepatol, 2009; 6(4): 217-227.
3. Lonardo A, Loria P, Adinolfi LE, et al. Hepatitis C and steatosis: a reappraisal [J]. J Viral Hepat, 2006; 13(2): 73-80.
4. 中華醫(yī)學(xué)會(huì)肝病學(xué)分會(huì)、中華醫(yī)學(xué)會(huì)傳染病與寄生蟲病學(xué)分會(huì). 丙型肝炎防治指南 [J]. 中華肝臟病雜志, 2004; 12(4): 194-198.
5. Rosenberg S. Recent advances in the molecular biology of hepatitis C virus [J]. J Mol Biol, 2001; 313(3): 451-464.
6. Castello G, Scala S, Palmieri G, et al. HCV-related hepatocellular carcinoma: From chronic inflammation to cancer [J]. Clin Immunol, 2010; 134(3): 237-250.
7. Zhu Z, Wilson AT, Gopalakrishna K, et al. Hepatitis C virus core protein enhances Telomerase activity in Huh7 cells [J]. J Med Virol, 2010; 82(2): 239-248.
8. Xu Z, Choi J, Yen TS, et al. Synthesis of a novel hepatitis C virus protein by ribosomal frameshift [J]. EMBO J, 2001; 20(14): 3840-3848.
9. Branch AD, Stump DD, Gutierrez JA, et al. The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others [J]. Semin Liver Dis, 2005; 25(1): 105-117.
10. Vassilaki N, Mavromara P. Two alternative translation mechanisms are responsible for the expression of the HCV ARFP/F/core+1 coding open reading frame [J]. J Biol Chem, 2003; 278(42): 40503-40513.
11. Boulant S, Becchi M, Penin F, et al. Unusual multiple recoding events leading to alternative forms of hepatitis C virus core protein from genotype 1b [J]. J Biol Chem, 2003; 278(46): 45785-45792.
12. Gao JH, He ZJ, Wang Q, et al. Low expression of S100P associated with paclitaxel resistance in ovarian cancer cell line [J]. Chin Med J (Engl), 2008; 121(16): 1563-1568.
13. Jiao J, Friedman SL, Aloman C. Hepatic fibrosis [J]. Curr Opin Gastroenterol, 2009; 25(3): 223-229.
14. Marra F, Aleffi S, Galastri S, et al. Mononuclear cells in liver fibrosis [J]. Semin Immunopathol, 2009; 31(3): 345-358.
15. Ghiassi-Nejad Z, Friedman SL. Advances in antifibrotic therapy [J]. Expert Rev Gastroenterol Hepatol, 2008; 2(6): 803-816.
16. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver [J]. Physiol Rev, 2008; 88(1): 125-172.
17. Kordes C, Sawitza I, Hussinger D. Hepatic and pancreatic stellate cells in focus [J]. Biol Chem, 2009; 390(10): 1003-1012.
18. Svegliati-Baroni G, De Minicis S, Marzioni M. Hepatic fibrogenesis in response to chronic liver injury: novel insights on the role of cell-to-cell interaction and transition [J]. Liver Int, 2008; 28(8): 1052-1064.
19. Hatok J, Babusikova E, Matakova T, et al. In vitro assays for the evaluation of drug resistance in tumor cells [J]. Clin Exp Med, 2009; 9(1): 1-7.
20. 劉穎, 梁惠, 蘇愛, 等. 海兔素對(duì)人胃癌細(xì)胞SGC-7901增殖和凋亡的影響 [J]. 中國(guó)藥理學(xué)通報(bào), 2010; 26(3): 333-337.
  1. 1. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome [J]. Science, 1989; 244(4902): 359-362.
  2. 2. Sklan EH, Charuworn P, Pang PS, et al. Mechanisms of HCV survival in the host [J]. Nat Rev Gastroenterol Hepatol, 2009; 6(4): 217-227.
  3. 3. Lonardo A, Loria P, Adinolfi LE, et al. Hepatitis C and steatosis: a reappraisal [J]. J Viral Hepat, 2006; 13(2): 73-80.
  4. 4. 中華醫(yī)學(xué)會(huì)肝病學(xué)分會(huì)、中華醫(yī)學(xué)會(huì)傳染病與寄生蟲病學(xué)分會(huì). 丙型肝炎防治指南 [J]. 中華肝臟病雜志, 2004; 12(4): 194-198.
  5. 5. Rosenberg S. Recent advances in the molecular biology of hepatitis C virus [J]. J Mol Biol, 2001; 313(3): 451-464.
  6. 6. Castello G, Scala S, Palmieri G, et al. HCV-related hepatocellular carcinoma: From chronic inflammation to cancer [J]. Clin Immunol, 2010; 134(3): 237-250.
  7. 7. Zhu Z, Wilson AT, Gopalakrishna K, et al. Hepatitis C virus core protein enhances Telomerase activity in Huh7 cells [J]. J Med Virol, 2010; 82(2): 239-248.
  8. 8. Xu Z, Choi J, Yen TS, et al. Synthesis of a novel hepatitis C virus protein by ribosomal frameshift [J]. EMBO J, 2001; 20(14): 3840-3848.
  9. 9. Branch AD, Stump DD, Gutierrez JA, et al. The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others [J]. Semin Liver Dis, 2005; 25(1): 105-117.
  10. 10. Vassilaki N, Mavromara P. Two alternative translation mechanisms are responsible for the expression of the HCV ARFP/F/core+1 coding open reading frame [J]. J Biol Chem, 2003; 278(42): 40503-40513.
  11. 11. Boulant S, Becchi M, Penin F, et al. Unusual multiple recoding events leading to alternative forms of hepatitis C virus core protein from genotype 1b [J]. J Biol Chem, 2003; 278(46): 45785-45792.
  12. 12. Gao JH, He ZJ, Wang Q, et al. Low expression of S100P associated with paclitaxel resistance in ovarian cancer cell line [J]. Chin Med J (Engl), 2008; 121(16): 1563-1568.
  13. 13. Jiao J, Friedman SL, Aloman C. Hepatic fibrosis [J]. Curr Opin Gastroenterol, 2009; 25(3): 223-229.
  14. 14. Marra F, Aleffi S, Galastri S, et al. Mononuclear cells in liver fibrosis [J]. Semin Immunopathol, 2009; 31(3): 345-358.
  15. 15. Ghiassi-Nejad Z, Friedman SL. Advances in antifibrotic therapy [J]. Expert Rev Gastroenterol Hepatol, 2008; 2(6): 803-816.
  16. 16. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver [J]. Physiol Rev, 2008; 88(1): 125-172.
  17. 17. Kordes C, Sawitza I, Hussinger D. Hepatic and pancreatic stellate cells in focus [J]. Biol Chem, 2009; 390(10): 1003-1012.
  18. 18. Svegliati-Baroni G, De Minicis S, Marzioni M. Hepatic fibrogenesis in response to chronic liver injury: novel insights on the role of cell-to-cell interaction and transition [J]. Liver Int, 2008; 28(8): 1052-1064.
  19. 19. Hatok J, Babusikova E, Matakova T, et al. In vitro assays for the evaluation of drug resistance in tumor cells [J]. Clin Exp Med, 2009; 9(1): 1-7.
  20. 20. 劉穎, 梁惠, 蘇愛, 等. 海兔素對(duì)人胃癌細(xì)胞SGC-7901增殖和凋亡的影響 [J]. 中國(guó)藥理學(xué)通報(bào), 2010; 26(3): 333-337.